Quick Answer
Jazz Pharmaceuticals plc reported Research And Development Expense of $299.73 million for the year ending 2019.
- Jazz Pharmaceuticals plc showed an increase of +32.3% in Research And Development Expense from 2018 to 2019.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 25, 2020.
- XBRL data for this metric is available from 2009 to 2019 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2009 to 2019), Jazz Pharmaceuticals plc's Research And Development Expense has grown by 719.8%.
- Historical annual values: Fiscal year 2019: $299.73 million | Fiscal year 2018: $226.62 million | Fiscal year 2017: $198.44 million | Fiscal year 2016: $162.30 million | Fiscal year 2015: $135.25 million | Fiscal year 2014: $85.18 million | Fiscal year 2013: $41.63 million | Fiscal year 2012: $20.48 million | Fiscal year 2011: $14.12 million | Fiscal year 2010: $25.61 million | Fiscal year 2009: $36.56 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: